[go: up one dir, main page]

WO2000017336A1 - Dna cassette encoding a multimer of a biologically active peptide and a cleavable linker attached thereto and process for preparing the biologically active peptide - Google Patents

Dna cassette encoding a multimer of a biologically active peptide and a cleavable linker attached thereto and process for preparing the biologically active peptide Download PDF

Info

Publication number
WO2000017336A1
WO2000017336A1 PCT/KR1999/000559 KR9900559W WO0017336A1 WO 2000017336 A1 WO2000017336 A1 WO 2000017336A1 KR 9900559 W KR9900559 W KR 9900559W WO 0017336 A1 WO0017336 A1 WO 0017336A1
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
cleavable
biologically active
dna cassette
protease
Prior art date
Application number
PCT/KR1999/000559
Other languages
French (fr)
Inventor
Sang Jun Lee
Original Assignee
Sang Jun Lee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sang Jun Lee filed Critical Sang Jun Lee
Priority to AU57626/99A priority Critical patent/AU5762699A/en
Publication of WO2000017336A1 publication Critical patent/WO2000017336A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/50Fusion polypeptide containing protease site
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Definitions

  • the present invention relates to a DNA cassette comprising two or more tandem repeating units of a nucleotide sequence encoding a biologically active peptide and a cleavable linker peptide attached thereto, an expression vector containing the DNA cassette, a microorganism transformed by the expression vector, and a process for preparing the biologically active peptide using the transformed microorganism.
  • the chemical synthesis method has been employed mainly for the production of very short peptides comprised of 2 to 10 amino acid residues. This chemical method is, however, ineffective and uneconomical when applied to the production of peptides having more than 10 amino acid residues.
  • the method of producing biologically active peptides in genetically engineered host microorganisms has been widely used for the production of long polypeptides having 100 to 400 amino acid residues, e.g., growth hormones, insulin and restriction enzymes.
  • this method is not suitable for preparing shorter peptides with less than 100 amino acid residues because of its inherent low productivity. Accordingly, there has existed a need to develop an economical process for preparing short biologically active peptides comprising 10 to 100 amino acid residues.
  • an object of the present invention to provide a novel DNA cassette containing multiple copies of a nucleotide sequence encoding a short peptide, an expression vector comprising the DNA cassette, a microorganism transformed by the vector, and a process for preparing the peptide using the transformed microorganism.
  • a DNA cassette which comprises two or more tandem repeating units of a nucleotide sequence encoding a biologically active peptide and a linker peptide attached thereto, said linker peptide being cleavable by a protease or a chemical agent.
  • Fig. 1 shows the DNA fragment obtained by annealing oligonucleotides 1 and 2 ;
  • Fig. 2 shows the procedure of designing the basic DNA unit .
  • Fig. 3 depicts the left adaptor obtained by annealing oligonucleotides 3 and 4;
  • Fig. 4 represents the right adaptor obtained by annealing oligonucleotides 5 and 6 ;
  • Fig. 5 reproduces the electrophoresis result of the 174 bp DNA cassette
  • Fig. 6 presents the DNA fragment obtained by annealing oligonucleotides 7 ;
  • Fig. 7 discloses the synthetic DNA fragment obtained by annealing oligonucleotides 8 and 9;
  • .. Fig. 8 describes the procedure for constructing vector pRSET-B-cGnRH-II' -4R * ;
  • Fig. 9 provides the nucleotide sequence of the DNA cassette contained in vector pRSET-B-cGnRH-II' -4R * ;
  • Fig. 10 offers the SDS-PAGE result of the 7.3 kDa protein expressed by vector pRSET-B-cGnRH-II' -4R * ;
  • Fig. 11 discloses the electrophoresis result of the peptides obtained by digesting the 7.3 kDa protein with trypsin.
  • a DNA cassette of the present invention comprises two or more tandem repeating units of a nucleotide sequence encoding a biologically active peptide and a linker peptide attached thereto, said linker peptide being cleavable by a protease or a chemical agent.
  • the biologically active peptide which may be used in the present invention includes any biologically active peptide comprised of 2 to 200 amino acids, preferably 10 to 100 amino acids.
  • Exemplary peptides include adrenocorticotropic hormone, angiotensin, atrial natriuretic peptide, bradykinin, chemotactic hormone, dynorphin, endorphin, enkephalin, fibronectin, ⁇ -lipotropin fragments, gastrointestinal peptide, growth hormone releasing peptide, luteinizing hormone releasing hormone such as gonadotropin releasing hormone, melanocyte stimulating hormone, neurotensin, opioid peptide, oxytocin, vasopressin, vasotocin, parathyroid hormone, somatostatin, substance P and antigenic peptide.
  • the linker peptide may have an amino acid residue or an amino acid sequence which is specifically recognized and digested by a protease or a chemical agent, thereby providing one or more cleavage sites.
  • a protease or a chemical agent thereby providing one or more cleavage sites.
  • Many protease- or chemical agent-digestible amino acid links and amino acid sequences are well known in the art of protein biochemistry; and representative examples thereof are shown in Table I.
  • 1 represents a peptide bond digested by a protease or chemical agent .
  • linker peptides may be designed as shown in Table II.
  • X is Ala, Arg, Asn, Asp, Cys, Glu, Gin, Gly, His, lie, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val ; and n is an integral number.
  • a linker peptide attached to a biologically active peptide is used as a basic repeating unit to prepare a tandem repetitive multimeric peptide which yields multiple copies of the biologically active peptide when digested by a protease or a chemical agent .
  • a biologically active peptide having a digestible C- terminal amino acid residue e.g., lysine, arginine, asparagine, glutamine and methionine, may also be used in the present invention as a basic repeating unit.
  • a nucleotide sequence encoding a basic repeating unit may be tandemly linked together to form a DNA cassette encoding a multimeric peptide.
  • the DNA cassette encoding the multimeric peptide may be obtained by ligating a basic DNA unit encoding the above mentioned basic repeating unit in accordance with a conventional ligation method (Sambrook et al . , Molecular Cloning: A Laboratory Manual, 2nd ed. , Cold Spring Harbor Laboratory Press, USA(1989)).
  • the basic DNA unit may be any of 5' -cohesive ended form, 3 '-cohesive ended form and blunt-ended form.
  • the 5' -cohesive ended form and 3' -cohesive ended form are preferred because of their ability to undergo a directional ligation to generate a DNA cassette having directional tandem repeats thereof.
  • Particularly preferred is a DNA fragment having a double stranded DNA region encoding a target peptide and complementary single strand DNA sequences of a linker peptide protruding from 5'- or 3'- ends thereof.
  • Such basic DNA unit may be obtained by chemically synthesizing a pair of complementary oligonucleotides encoding the basic repeating unit and annealing the oligonucleotides in accordance with a conventional annealing method (Sambrook et al . , vide supra) .
  • the nucleotide sequence of a basic DNA unit encoding a basic repeating unit may be deduced from the amino acid sequences of the target peptide and the linker peptide contained in the basic repeating unit based on the standard genetic code.
  • the nucleotide sequence encoding a basic repeating unit may be further modified without changing the amino acid sequence so as to minimize the free energy of the secondary structure of RNA transcribed therefrom in case of N-terminal basic repeating unit, thereby increasing the expression efficiency thereof; or to lower the nucleotide homology between repeating nucleotide sequences; or to provide one or more preferred codons .
  • the basic DNA unit which may be used in the ligation reaction has a nucleotide sequence encoding a repeating unit and various modified forms thereof.
  • the DNA cassette of the present invention may be obtained by ligating in tandem a suitable number of basic DNA units encoding the basic repeating unit, the number ranging from 2 to 20, preferably 2 to 10.
  • Such cassette encodes a multimeric peptide containing multiple copies of the basic repeating unit in tandem; and it may further contain an additional nucleotide sequence encoding a stuffer amino acid in the linker peptide region to modify the charge or hydrophobicity of the multimeric peptide.
  • the vector of the present invention which is capable of expressing a multimeric peptide, may be obtained by inserting the DNA cassette containing a nucleotide sequence encoding a multimeric peptide in an expression vector according to a conventional cloning method (Sambrook et al . , vide supra) .
  • suitable adaptors may be attached to the DNA cassette in order to facilitate the cloning thereof before the insertion.
  • the expression vector thus obtained may be introduced into a host microorganism such as E ⁇ _ coli , in accordance with a conventional transformation method (Sambrook et al . , the supra) .
  • a biologically active peptide or an analog thereof may be efficiently prepared by (a) culturing the transformed microorganism to produce a multimeric peptide expressed by the DNA cassette; (b) recovering the multimeric peptide from the culture; and (c) digesting the multimeric peptide with a protease or a chemical agent to obtain the biologically active peptide or the analog thereof, carrying one or more amino acid residues originating from the linker peptide.
  • the transformed host microorganism may be cultured in accordance with a conventional method (Sambrook et al . , the supra) to express the multimeric peptide.
  • the expression may be induced using an appropriate inducer, e.g., isopropyl-1-thio- ⁇ -D-galactoside.
  • the microorganism cell culture may be centrifuged or filtered to harvest microorganism cells.
  • the cells are then lysed; and the multimeric peptide may be isolated therefrom by a conventional method (Methods in Enzvmoloqy, volume 182, Edited by Murray D. Deutscher, Academic press, Inc., New York, USA), e.g., ion exchange chromatography or gel filtration column chromatography, preferably anion exchange fast protein liquid chromatography, and, more preferably, Mono-Q anion exchange fast liquid chromatography (Pharmacia LKB, Sweden) .
  • the purified multimeric peptide may be digested with an appropriate protease or chemical agent in accordance with a conventional digestion method (Methods in Enzvmoloqy, vide supra) to obtain a biologically active peptide, or an analog having one or more linker peptide-derived amino acids attached to N- or C-terminus thereof.
  • a trypsin-digestible linker peptide represented by following amino acid sequence (SEQ ID NO: 1) was designed.
  • cGnRH-II' has the structure of linker peptide-cGnRH-II-linker peptide.
  • a basic DNA unit encoding cGnRH-II' the following pair of complementary oligonucleotides were synthesized and annealed to obtain a basic DNA unit shown in Fig. 1 which consists of a double stranded (ds) region encoding cGnRH-II and two single stranded (ss) regions protruding from both 3' ends thereof encoding the linker peptide, the two single strands being complementary to each other.
  • ds double stranded
  • ss single stranded
  • sense strand oligonucleotide 1 SEQ ID NO: 5
  • antisense strand oligonucleotide 2 SEQ ID NO: 6
  • Fig. 2 shows the procedure of designing the basic DNA unit .
  • This basic DNA unit was employed as a monomer in the preparation of a DNA cassette encoding a multimeric peptide composed of repeating units of (cGnRH-II -linker peptide) .
  • a left adaptor useful for cloning the DNA fragment obtained in Preparation Example 1 the following pair of complementary oligonucleotides were synthesized and annealed to obtain a left adaptor shown in Fig. 3 which consists of a 5 ' -protruding ss region having EcoRI site, a ds region having BamHI and Xmal/Smal sites, and a 3'- protruding ss region having a nucleotide sequence encoding the linker peptide.
  • oligonucleotide 3 (SEQ ID NO: 8) : 5 ' -AATTCAAGGATCCCCCGGGGGGAAGAGA-3 ' oligonucleotide 4 (SEQ ID NO: 9) : 5 ' -CCCGGGGGATTCTTG-3 '
  • oligonucleotide 5 (SEQ ID NO: 10) : 5 ' -CTCGAGAAGCTTACG-3 ' oligonucleotide 6 (SEQ ID NO: 11) : 5 ' -TCGACGTAAGCTTCTCGAGTCTCTTCCC-3 '
  • the basic DNA unit obtained in Preparation Example 1 was self-ligated at 16 °C for 2 hours to obtain a DNA cassette comprised of tandem repeats of the DNA unit.
  • the DNA cassette was ligated with the left and right adaptors obtained in Preparation Examples 2 and 3, respectively, using T4 DNA ligase at 16 °C for 2 hours to obtain a DNA cassette.
  • the DNA cassette was inserted in the EcoRl/Sall sites of plasmid pUC19 (Yanish-Peron, C. et al . , Gene, 33, 103-119(1985)).
  • E ⁇ coli JM109 was transformed with the plasmid.
  • the transformant E ⁇ . coli was cultured in LB medium (bacto-yeast extract 5 g, bacto-tryptone 10 g, NaCl 5 g and agar 15 g(pH7.2) per I ) containing 50 ⁇ g/ml ampicillin at 37 °C overnight. Plasmid DNA was purified from the culture and cleaved with EcoRI and Sail. DNA fragments thus obtained were subjected to electrophoresis on 3% metaphor agarose gel (FMC Co., USA).
  • Fig. 5 reproduces the result of electrophoresis wherein lane 1 represents a 47 bp DNA fragment which is obtained by ligating the left and right adaptors; lane 2, a 86 bp DNA cassette which results from the ligation of the left adaptor, the basic DNA unit and the right adaptor; lane 3, a 174 bp DNA cassette which is the product of ligating the left adaptor, three basic DNA units and the right adaptor; and lane 4, a lkb ladder DNA molecular size markers.
  • the plasmid containing 174 bp DNA cassette was designated pUC19-cGnRH-II ' -3R.
  • Plasmid pUC19-cGnRH-II' -3R obtained in Example 1 was cleaved with BamHI and Hindlll and the DNA cassette thus obtained was inserted in the BamHI/Hindlll sites of expression vector pRSET-B (Invitrogen Co., USA) to obtain vector pRSET-B-cGnRH-II' -3R.
  • Step 2 Addition of a termination codon to a DNA cassette
  • a DNA fragment containing a termination codon which is shown in Fig. 6, was prepared by annealing the following self- complementary oligonucleotide 7 (SEQ ID NO: 12) , which provides a termination codon (TGA), an Ndel site and an Xmal site, and the DNA fragment thus obtained was inserted in the Hindlll site of vector pRSET-B-cGnRH-II ' -3R obtained in Step 1, to obtain vector pRSET-B-cGnRH-II' -3R * .
  • RNA secondary structure (computer program DNASISTM, Hitachi, Japan), and using the DNA fragment thus obtained the Ndel/Xmal fragment of vector pRSET-B-cGnRH-II ' -3R * obtained in Step 2 was replaced, to obtain vector pRSET-B-cGnRH-II' -4R * .
  • oligonucleotide 8 (SEQ ID NO: 13) : 5 ' -TATGGGCAAACGAGAGCATTGGTCACACGGGTGGTACC-3 ' oligonucleotide 9 (SEQ ID NO: 14) :
  • Fig. 8 describes the procedure for constructing vector pRSET-B-cGnRH-II' -4R * wherein C shows a basic DNA unit; ⁇ C, modified basic DNA unit; L, a left adaptor; R, a right adaptor; and S, a termination codon.
  • the nucleotide sequence of the DNA cassette contained in vector pRSET-B-cGnRH-II ' -4R * was determined using the dideoxy-mediated chain-termination method (Sanger, F. et al . , Proc. Natl. Acad. Sci . USA, 74, 5463-5467 (1977)).
  • the resulting nucleotide sequence (SEQ ID NO: 15) of the DNA cassette is shown below and details of the sequence are represented in Fig. 9 wherein i shows the trypsin-digestible site; and ***, the termination codon.
  • the DNA cassette of vector pRSET-B-cGnRH-II ' -4R * consists of 183 bp nucleotides which contains four repeats of the nucleotide sequence encoding the repeating unit of (cGnRH-II-linker peptide) arranged in an open reading frame and a termination codon.
  • E. coli TOP10F' (Invitrogen Co., USA) was transformed with vector pRSET-B-cGnRH-II' -4R * to obtain transformant E. coli cGnRH-II' -4R * .
  • Transformant E ⁇ coli cGnRH-II' -4R * obtained in Example 2 was cultured in SOB medium (tryptone 20 g, yeast extract 5.0 g, NaCl 0.5 g and KCl 1.86 mg per 1 2 ) containing 50 ⁇ g/ml ampicillin at 37 °C overnight.
  • SOB medium tryptone 20 g, yeast extract 5.0 g, NaCl 0.5 g and KCl 1.86 mg per 1 2
  • the resulting culture was diluted 200 fold with SOB medium and then incubated at 37 °C.
  • isopropyl-1-thio- ⁇ -D-galactoside was added thereto to a concentration of 1 mM.
  • 5 pfu/cell of M13/T7 phage Invitrogen Co., USA
  • the phage infected culture was incubated for 5 hours to express the DNA cassette.
  • lane 10 reproduces the result of SDS-PAGE, wherein lane 1 shows protein size markers; lane 2, proteins expressed in E. coli transformed with vector pRSET-B-cGnRH-II ' -3R * ; lane 3, proteins expressed in E ⁇ coli transformed with vector pRSET-B-cGnRH-II' -4R * .
  • lane 1 shows protein size markers
  • lane 2 proteins expressed in E. coli transformed with vector pRSET-B-cGnRH-II ' -3R *
  • lane 3 proteins expressed in E ⁇ coli transformed with vector pRSET-B-cGnRH-II' -4R * .
  • vector pRSET-B-cGnRH-II' -3R * expresses a low level of 9.2 kDa protein while vector pRSET-B-cGnRH-II' -4R * expresses a protein having a size of 8.0 kDa which is close to 7.3 kDa estimated for the DNA cassette shown in Fig. 9.
  • Example 3 The culture obtained in Example 3 was centrifuged at 2,000 x g for 20 min. at 4 °C to harvest E ⁇ . coli cells.
  • the E. coli cells were washed twice with cold 20mM Tris-HCl buffer (pH 8.0) and suspended in 1/10 volume of the original culture. The resulting suspension was subjected to fast protein liquid chromatography.
  • Proteins were adsorbed on a Mono Q 5/5 anion exchange column (Pharmacia LKB, Sweden) pre- equilibrated with 100% buffer A(20 mM Tris-HCl (pH 8.0)) and eluted at a flow rate of 1 ml/min with a linear gradient generated using 100% buffer A and 100% buffer B(20mM Tris- HCl at pH 8.0 containing 1.0M NaCl) .
  • Combined protein fractions were desalted by dialyzing against 20 mM Tris- HCl (pH 8.0) and lyophilized. The lyophilized powder was resuspended in 20 mM Tris-HCl (pH 8.0) and then digested with trypsin at room temperature for 3 hours.
  • the digested protein was subjected to electrophoresis on Tricine gel having a concentration gradient from 10 to 20%(Novex, USA) .
  • the results are shown in Fig. 11, wherein lane 1 shows a 7.3 kDa protein; lanes 5, the peptide obtained by digesting the 7.3 kDa protein with trypsin; and lane 6, trypsin.
  • the 7.3 kDa protein is a tandem repetitive multimer of the 1.4 kDa monomer peptide.
  • the 1.4 kDa peptide was transferred to a polyvmylidene difluoride membrane (Matsudaria, 1987) and the amino acid sequence was determined with a protein sequencer (Applied Biosystem, model 476A, USA) in a pulse- liquid mode.
  • the resulting sequence (SEQ ID NO: 16) of the 1.4 kDa peptide is shown below.
  • the 1.4 kDa peptide is a cGnRH-II analog consisting of cGnRH-II having the linker-derived Gly-Lys sequence attached to the C-terminus .

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A biologically active peptide is prepared by: a) preparing an expression vector comprising a DNA cassette containing two or more tandem repeating units of a nucleotide sequence encoding a biologically active peptide and a linker peptide attached thereto, the linker peptide being cleavable by a protease or a chemical agent; b) transforming a microorganism with the expression vector; c) culturing the transformed microorganism to produce a multimeric peptide expressed by the DNA cassette; d) recovering and digesting the multimeric peptide with the protease or the chemical agent to obtain the biologically active peptide or an analog thereof carrying one or more amino acid residues originating from the linker peptide.

Description

DNA CASSETTE ENCODING A MULTIMER OF A BIOLOGICALLY ACTIVE - PEPTIDE AND A CLEAVABLE LINKER ATTACHED THERETO AND PROCESS FOR PREPARING THE BIOLOGICALLY ACTIVE PEPTIDE
FIELD OF THE INVENTION
The present invention relates to a DNA cassette comprising two or more tandem repeating units of a nucleotide sequence encoding a biologically active peptide and a cleavable linker peptide attached thereto, an expression vector containing the DNA cassette, a microorganism transformed by the expression vector, and a process for preparing the biologically active peptide using the transformed microorganism.
BACKGROUND OF THE INVENTION
Many biologically active peptides such as enzymes and hormones have been produced by chemical synthesis or by in vivo synthesis using genetically engineered host microorganisms .
The chemical synthesis method has been employed mainly for the production of very short peptides comprised of 2 to 10 amino acid residues. This chemical method is, however, ineffective and uneconomical when applied to the production of peptides having more than 10 amino acid residues.
The method of producing biologically active peptides in genetically engineered host microorganisms, on the other hand, has been widely used for the production of long polypeptides having 100 to 400 amino acid residues, e.g., growth hormones, insulin and restriction enzymes. However, this method is not suitable for preparing shorter peptides with less than 100 amino acid residues because of its inherent low productivity. Accordingly, there has existed a need to develop an economical process for preparing short biologically active peptides comprising 10 to 100 amino acid residues.
SUMMARY OF THE INVENTION
It is, therefore, an object of the present invention to provide a novel DNA cassette containing multiple copies of a nucleotide sequence encoding a short peptide, an expression vector comprising the DNA cassette, a microorganism transformed by the vector, and a process for preparing the peptide using the transformed microorganism.
In accordance with one aspect of the present invention, there is provided a DNA cassette which comprises two or more tandem repeating units of a nucleotide sequence encoding a biologically active peptide and a linker peptide attached thereto, said linker peptide being cleavable by a protease or a chemical agent.
BRIEF DESCRIPTION OF THE DRAWINGS
The above objects and features of the present invention will become apparent from the following description of preferred embodiments taken in conjunction with the accompanying drawings, in which:
Fig. 1 shows the DNA fragment obtained by annealing oligonucleotides 1 and 2 ;
Fig. 2 shows the procedure of designing the basic DNA unit .
Fig. 3 depicts the left adaptor obtained by annealing oligonucleotides 3 and 4; Fig. 4 represents the right adaptor obtained by annealing oligonucleotides 5 and 6 ;
Fig. 5 reproduces the electrophoresis result of the 174 bp DNA cassette;
Fig. 6 presents the DNA fragment obtained by annealing oligonucleotides 7 ;
Fig. 7 discloses the synthetic DNA fragment obtained by annealing oligonucleotides 8 and 9;
.. Fig. 8 describes the procedure for constructing vector pRSET-B-cGnRH-II' -4R*;
Fig. 9 provides the nucleotide sequence of the DNA cassette contained in vector pRSET-B-cGnRH-II' -4R*;
Fig. 10 offers the SDS-PAGE result of the 7.3 kDa protein expressed by vector pRSET-B-cGnRH-II' -4R*; and
Fig. 11 discloses the electrophoresis result of the peptides obtained by digesting the 7.3 kDa protein with trypsin.
DETAILED DESCRIPTION OF THE INVENTION
A DNA cassette of the present invention comprises two or more tandem repeating units of a nucleotide sequence encoding a biologically active peptide and a linker peptide attached thereto, said linker peptide being cleavable by a protease or a chemical agent.
The biologically active peptide which may be used in the present invention includes any biologically active peptide comprised of 2 to 200 amino acids, preferably 10 to 100 amino acids. Exemplary peptides include adrenocorticotropic hormone, angiotensin, atrial natriuretic peptide, bradykinin, chemotactic hormone, dynorphin, endorphin, enkephalin, fibronectin, β-lipotropin fragments, gastrointestinal peptide, growth hormone releasing peptide, luteinizing hormone releasing hormone such as gonadotropin releasing hormone, melanocyte stimulating hormone, neurotensin, opioid peptide, oxytocin, vasopressin, vasotocin, parathyroid hormone, somatostatin, substance P and antigenic peptide.
The linker peptide may have an amino acid residue or an amino acid sequence which is specifically recognized and digested by a protease or a chemical agent, thereby providing one or more cleavage sites. Many protease- or chemical agent-digestible amino acid links and amino acid sequences are well known in the art of protein biochemistry; and representative examples thereof are shown in Table I.
Table I
Figure imgf000006_0001
*
1 represents a peptide bond digested by a protease or chemical agent .
Using one or more digestible amino acid links and amino acid sequences as set forth above, various linker peptides may be designed as shown in Table II.
Table II
Figure imgf000007_0001
* X is Ala, Arg, Asn, Asp, Cys, Glu, Gin, Gly, His, lie, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val ; and n is an integral number.
A linker peptide attached to a biologically active peptide is used as a basic repeating unit to prepare a tandem repetitive multimeric peptide which yields multiple copies of the biologically active peptide when digested by a protease or a chemical agent .
A biologically active peptide having a digestible C- terminal amino acid residue, e.g., lysine, arginine, asparagine, glutamine and methionine, may also be used in the present invention as a basic repeating unit.
A nucleotide sequence encoding a basic repeating unit may be tandemly linked together to form a DNA cassette encoding a multimeric peptide.
The DNA cassette encoding the multimeric peptide may be obtained by ligating a basic DNA unit encoding the above mentioned basic repeating unit in accordance with a conventional ligation method (Sambrook et al . , Molecular Cloning: A Laboratory Manual, 2nd ed. , Cold Spring Harbor Laboratory Press, USA(1989)).
The basic DNA unit may be any of 5' -cohesive ended form, 3 '-cohesive ended form and blunt-ended form. Among those, the 5' -cohesive ended form and 3' -cohesive ended form are preferred because of their ability to undergo a directional ligation to generate a DNA cassette having directional tandem repeats thereof. Particularly preferred is a DNA fragment having a double stranded DNA region encoding a target peptide and complementary single strand DNA sequences of a linker peptide protruding from 5'- or 3'- ends thereof. Such basic DNA unit may be obtained by chemically synthesizing a pair of complementary oligonucleotides encoding the basic repeating unit and annealing the oligonucleotides in accordance with a conventional annealing method (Sambrook et al . , vide supra) . The nucleotide sequence of a basic DNA unit encoding a basic repeating unit may be deduced from the amino acid sequences of the target peptide and the linker peptide contained in the basic repeating unit based on the standard genetic code. The nucleotide sequence encoding a basic repeating unit may be further modified without changing the amino acid sequence so as to minimize the free energy of the secondary structure of RNA transcribed therefrom in case of N-terminal basic repeating unit, thereby increasing the expression efficiency thereof; or to lower the nucleotide homology between repeating nucleotide sequences; or to provide one or more preferred codons .
Therefore, the basic DNA unit which may be used in the ligation reaction has a nucleotide sequence encoding a repeating unit and various modified forms thereof.
The DNA cassette of the present invention may be obtained by ligating in tandem a suitable number of basic DNA units encoding the basic repeating unit, the number ranging from 2 to 20, preferably 2 to 10. Such cassette encodes a multimeric peptide containing multiple copies of the basic repeating unit in tandem; and it may further contain an additional nucleotide sequence encoding a stuffer amino acid in the linker peptide region to modify the charge or hydrophobicity of the multimeric peptide.
The vector of the present invention, which is capable of expressing a multimeric peptide, may be obtained by inserting the DNA cassette containing a nucleotide sequence encoding a multimeric peptide in an expression vector according to a conventional cloning method (Sambrook et al . , vide supra) . In this process, suitable adaptors may be attached to the DNA cassette in order to facilitate the cloning thereof before the insertion.
The expression vector thus obtained may be introduced into a host microorganism such as E^_ coli , in accordance with a conventional transformation method (Sambrook et al . , the supra) .
A biologically active peptide or an analog thereof may be efficiently prepared by (a) culturing the transformed microorganism to produce a multimeric peptide expressed by the DNA cassette; (b) recovering the multimeric peptide from the culture; and (c) digesting the multimeric peptide with a protease or a chemical agent to obtain the biologically active peptide or the analog thereof, carrying one or more amino acid residues originating from the linker peptide.
The transformed host microorganism may be cultured in accordance with a conventional method (Sambrook et al . , the supra) to express the multimeric peptide. The expression may be induced using an appropriate inducer, e.g., isopropyl-1-thio-β-D-galactoside.
The microorganism cell culture may be centrifuged or filtered to harvest microorganism cells. The cells are then lysed; and the multimeric peptide may be isolated therefrom by a conventional method (Methods in Enzvmoloqy, volume 182, Edited by Murray D. Deutscher, Academic press, Inc., New York, USA), e.g., ion exchange chromatography or gel filtration column chromatography, preferably anion exchange fast protein liquid chromatography, and, more preferably, Mono-Q anion exchange fast liquid chromatography (Pharmacia LKB, Sweden) .
The purified multimeric peptide may be digested with an appropriate protease or chemical agent in accordance with a conventional digestion method (Methods in Enzvmoloqy, vide supra) to obtain a biologically active peptide, or an analog having one or more linker peptide-derived amino acids attached to N- or C-terminus thereof.
The following Preparation Examples and Examples are intended to further illustrate the present invention without limiting its scope.
Preparation Example 1; Preparation of Basic DNA Unit
A trypsin-digestible linker peptide represented by following amino acid sequence (SEQ ID NO: 1) was designed.
Gly Lys Arg
Based on the amino acid sequences of chicken gonadotropin releasing hormone II (designated cGnRH-II;
Miyamoto et al . , Proc . Natl. Acad. Sci. USA, 81, 3874-3878
(1984) ) and the above linker peptide, a basic peptide unit represented by following amino acid sequence was designed. This unit, designated cGnRH-II' , has the structure of linker peptide-cGnRH-II-linker peptide.
cGnRH-II(SEQ ID NO: 2):
Glu His Trp Ser His Gly Trp Tyr Pro Gly 5 10 cGnRH-II' (linker peptide-cGnRH-II-linker peptide) (SEQIDNO: 3) :
Gly Lys Arg Glu His Trp Ser His Gly Trp Tyr Pro Gly Gly Lys
5 10 15 Arg
Using the standard genetic codes, a DNA fragment having the following nucleotide sequence (SEQ ID NO: 4) was deduced to match cGnRH-II' .
5 ' -GGGAAGAGAGAGCACTGGTCCCACGGGTGGTACCCAGGCGGGAAGAGA-3
To obtain a basic DNA unit encoding cGnRH-II', the following pair of complementary oligonucleotides were synthesized and annealed to obtain a basic DNA unit shown in Fig. 1 which consists of a double stranded (ds) region encoding cGnRH-II and two single stranded (ss) regions protruding from both 3' ends thereof encoding the linker peptide, the two single strands being complementary to each other.
sense strand oligonucleotide 1 (SEQ ID NO: 5) : 5 ' -GAGCACTGGTCCCACGGGTGGTACCCAGGCGGGAAGAGA-3 ' antisense strand oligonucleotide 2 (SEQ ID NO: 6) : 5 ' -GCCTGGTGACCACCCGTGGGACCAGTGCTCTCTCTTCCC-3 '
Fig. 2 shows the procedure of designing the basic DNA unit .
This basic DNA unit was employed as a monomer in the preparation of a DNA cassette encoding a multimeric peptide composed of repeating units of (cGnRH-II -linker peptide) .
Preparation Example 2: Preparation of Left Adaptor
For preparing a left adaptor useful for cloning the DNA fragment obtained in Preparation Example 1, the following pair of complementary oligonucleotides were synthesized and annealed to obtain a left adaptor shown in Fig. 3 which consists of a 5 ' -protruding ss region having EcoRI site, a ds region having BamHI and Xmal/Smal sites, and a 3'- protruding ss region having a nucleotide sequence encoding the linker peptide.
oligonucleotide 3 (SEQ ID NO: 8) : 5 ' -AATTCAAGGATCCCCCGGGGGGAAGAGA-3 ' oligonucleotide 4 (SEQ ID NO: 9) : 5 ' -CCCGGGGGATTCTTG-3 '
Preparation Example 3 : Preparation of Right Adaptor
The procedure of Preparation Example 2 was repeated except for using the following pair of complementary oligonucleotides, to obtain a right adaptor shown in Fig. 4 which consists of a 3 ' -protruding ss region having a nucleotide sequence complementary to that the encoding linker peptide, a ds region having Xhol and Hindlll sites, and a 5' -protruding ss region having Sail site.
oligonucleotide 5 (SEQ ID NO: 10) : 5 ' -CTCGAGAAGCTTACG-3 ' oligonucleotide 6 (SEQ ID NO: 11) : 5 ' -TCGACGTAAGCTTCTCGAGTCTCTTCCC-3 '
Example 1 : Construction of DNA Cassette
The basic DNA unit obtained in Preparation Example 1 was self-ligated at 16 °C for 2 hours to obtain a DNA cassette comprised of tandem repeats of the DNA unit.
The DNA cassette was ligated with the left and right adaptors obtained in Preparation Examples 2 and 3, respectively, using T4 DNA ligase at 16 °C for 2 hours to obtain a DNA cassette. The DNA cassette was inserted in the EcoRl/Sall sites of plasmid pUC19 (Yanish-Peron, C. et al . , Gene, 33, 103-119(1985)). E^ coli JM109 was transformed with the plasmid.
The transformant E^. coli was cultured in LB medium (bacto-yeast extract 5 g, bacto-tryptone 10 g, NaCl 5 g and agar 15 g(pH7.2) per I ) containing 50 μg/ml ampicillin at 37 °C overnight. Plasmid DNA was purified from the culture and cleaved with EcoRI and Sail. DNA fragments thus obtained were subjected to electrophoresis on 3% metaphor agarose gel (FMC Co., USA).
Fig. 5 reproduces the result of electrophoresis wherein lane 1 represents a 47 bp DNA fragment which is obtained by ligating the left and right adaptors; lane 2, a 86 bp DNA cassette which results from the ligation of the left adaptor, the basic DNA unit and the right adaptor; lane 3, a 174 bp DNA cassette which is the product of ligating the left adaptor, three basic DNA units and the right adaptor; and lane 4, a lkb ladder DNA molecular size markers.
The plasmid containing 174 bp DNA cassette was designated pUC19-cGnRH-II ' -3R.
Example 2 : Construction of Expression Vector containing DNA Cassette
(Step 1) Insertion of a DNA cassette into an expression vector
Plasmid pUC19-cGnRH-II' -3R obtained in Example 1 was cleaved with BamHI and Hindlll and the DNA cassette thus obtained was inserted in the BamHI/Hindlll sites of expression vector pRSET-B (Invitrogen Co., USA) to obtain vector pRSET-B-cGnRH-II' -3R.
(Step 2) Addition of a termination codon to a DNA cassette
To add a termination codon to the DNA cassette, a DNA fragment containing a termination codon, which is shown in Fig. 6, was prepared by annealing the following self- complementary oligonucleotide 7 (SEQ ID NO: 12) , which provides a termination codon (TGA), an Ndel site and an Xmal site, and the DNA fragment thus obtained was inserted in the Hindlll site of vector pRSET-B-cGnRH-II ' -3R obtained in Step 1, to obtain vector pRSET-B-cGnRH-II' -3R*.
5 ' -AGCTTTGACAGCTGTCAA-3 '
(Step 3) Addition of a modified basic DNA unit
To increase the expression efficiency of the DNA cassette, the following complementary oligonucleotides were synthesized and annealed to obtain a synthetic DNA fragment shown in Fig. 7, which encodes methionine-linker peptide- cGnRH-II with a lower ΔG value for RNA secondary structure (computer program DNASIS™, Hitachi, Japan), and using the DNA fragment thus obtained the Ndel/Xmal fragment of vector pRSET-B-cGnRH-II ' -3R* obtained in Step 2 was replaced, to obtain vector pRSET-B-cGnRH-II' -4R*.
oligonucleotide 8 (SEQ ID NO: 13) : 5 ' -TATGGGCAAACGAGAGCATTGGTCACACGGGTGGTACC-3 ' oligonucleotide 9 (SEQ ID NO: 14) :
5 ' -CCCGGGTACCACCCGTGTGACCAATGCTCTCGTTTGCCCAT-3 '
Fig. 8 describes the procedure for constructing vector pRSET-B-cGnRH-II' -4R* wherein C shows a basic DNA unit; ΔC, modified basic DNA unit; L, a left adaptor; R, a right adaptor; and S, a termination codon.
The nucleotide sequence of the DNA cassette contained in vector pRSET-B-cGnRH-II ' -4R* was determined using the dideoxy-mediated chain-termination method (Sanger, F. et al . , Proc. Natl. Acad. Sci . USA, 74, 5463-5467 (1977)). The resulting nucleotide sequence (SEQ ID NO: 15) of the DNA cassette is shown below and details of the sequence are represented in Fig. 9 wherein i shows the trypsin-digestible site; and ***, the termination codon.
5 ' -ATGGGCAAACGAGAGCATTGGTCACACGGGTGGTACCCCGGGGGGAAGAGAGAGC ACTGGTCCCACGGGTGGTACCCAGGCGGGAAGAGAGAGCACTGGTCCCACGGGTGGTA CCCAGGCGGGAAGAGAGAGCACTGGTCCCACGGGTGGTACCCAGGCGGGAAGAGACTC GAGAAGCTTTGACAGCTGTCAAAGCTT-3 '
As can be seen in above nucleotide sequence and Fig. 9, the DNA cassette of vector pRSET-B-cGnRH-II ' -4R* consists of 183 bp nucleotides which contains four repeats of the nucleotide sequence encoding the repeating unit of (cGnRH-II-linker peptide) arranged in an open reading frame and a termination codon.
E. coli TOP10F' (Invitrogen Co., USA) was transformed with vector pRSET-B-cGnRH-II' -4R* to obtain transformant E. coli cGnRH-II' -4R*.
Example 3 : Expression of the DNA cassette
Transformant E^ coli cGnRH-II' -4R* obtained in Example 2 was cultured in SOB medium (tryptone 20 g, yeast extract 5.0 g, NaCl 0.5 g and KCl 1.86 mg per 1 2 ) containing 50 μg/ml ampicillin at 37 °C overnight. The resulting culture was diluted 200 fold with SOB medium and then incubated at 37 °C. When the optical density at 600 nm reached 0.3, isopropyl-1-thio-β-D-galactoside was added thereto to a concentration of 1 mM. 5 pfu/cell of M13/T7 phage (Invitrogen Co., USA) was added thereto, and the phage infected culture was incubated for 5 hours to express the DNA cassette.
1 ml of the culture was centrifuged at 6,000 rpm for 5 min to obtain a pellet and the pellet was suspended in 200 μl of buffer(0.05M Tris-HCl, pH 6.8 , 0.1M DTT, 2% SDS, 1% glycerol, and 0.1% bromophenol blue). The suspension was heated at 90 °C for 5 min. and 10 μl thereof was subjected to sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE) on 16% gel(Laemmli, U.K., Nature, 227, 680-685 (1970) ) . Fig. 10 reproduces the result of SDS-PAGE, wherein lane 1 shows protein size markers; lane 2, proteins expressed in E. coli transformed with vector pRSET-B-cGnRH-II ' -3R*; lane 3, proteins expressed in E^ coli transformed with vector pRSET-B-cGnRH-II' -4R*. As can be seen in Fig. 10, vector pRSET-B-cGnRH-II' -3R* expresses a low level of 9.2 kDa protein while vector pRSET-B-cGnRH-II' -4R* expresses a protein having a size of 8.0 kDa which is close to 7.3 kDa estimated for the DNA cassette shown in Fig. 9.
Example 4 : Production of cGnRH-II analog
The culture obtained in Example 3 was centrifuged at 2,000 x g for 20 min. at 4 °C to harvest E^. coli cells. The E. coli cells were washed twice with cold 20mM Tris-HCl buffer (pH 8.0) and suspended in 1/10 volume of the original culture. The resulting suspension was subjected to fast protein liquid chromatography. Proteins were adsorbed on a Mono Q 5/5 anion exchange column (Pharmacia LKB, Sweden) pre- equilibrated with 100% buffer A(20 mM Tris-HCl (pH 8.0)) and eluted at a flow rate of 1 ml/min with a linear gradient generated using 100% buffer A and 100% buffer B(20mM Tris- HCl at pH 8.0 containing 1.0M NaCl) . Combined protein fractions were desalted by dialyzing against 20 mM Tris- HCl (pH 8.0) and lyophilized. The lyophilized powder was resuspended in 20 mM Tris-HCl (pH 8.0) and then digested with trypsin at room temperature for 3 hours.
The digested protein was subjected to electrophoresis on Tricine gel having a concentration gradient from 10 to 20%(Novex, USA) . The results are shown in Fig. 11, wherein lane 1 shows a 7.3 kDa protein; lanes 5, the peptide obtained by digesting the 7.3 kDa protein with trypsin; and lane 6, trypsin. As can be seen in Fig. 11, the 7.3 kDa protein is a tandem repetitive multimer of the 1.4 kDa monomer peptide.
In order to examine the amino acid sequence of 1.4 kDa peptide, the 1.4 kDa peptide was transferred to a polyvmylidene difluoride membrane (Matsudaria, 1987) and the amino acid sequence was determined with a protein sequencer (Applied Biosystem, model 476A, USA) in a pulse- liquid mode. The resulting sequence (SEQ ID NO: 16) of the 1.4 kDa peptide is shown below.
Glu His Trp Ser His Gly Trp Tyr Pro Gly Gly Lys
5 10
As can be seen from the above amino acid sequence, the 1.4 kDa peptide is a cGnRH-II analog consisting of cGnRH-II having the linker-derived Gly-Lys sequence attached to the C-terminus .
While the invention has been described with respect to the above specific embodiments, it should be recognized that various modifications and changes may be made to the invention by those skilled in the art which also fall within the scope of the invention as defined by the appended claims.

Claims

What is claimed is:
1. A DNA cassette which comprises two or more tandem repeating units of a nucleotide sequence encoding a biologically active peptide and a linker peptide attached thereto, the linker peptide being cleavable by a protease or a chemical agent.
2. The DNA cassette of claim 1, wherein the biologically active peptide is comprised of 2 to 200 amino acid residues.
3. The DNA cassette of claim 2, wherein the biologically active peptide is selected from the group consisting of adrenocorticotropic hormone, angiotensin, atrial natriuretic peptide, bradykinin, chemotactic hormone, dynorphin, endorphin, enkephalin, fibronectin, β-lipotropin fragments, gastrointestinal peptide, growth hormone releasing peptide, luteinizing hormone releasing hormone, melanocyte stimulating hormone, neurotensin, opioid peptide, oxytocin, vasopressin, vasotocin, parathyroid hormone, somatostatin, substance P and antigenic peptide.
4. The DNA cassette of claim 3 , wherein the biologically active peptide is chicken gonadotropin releasing hormone II.
5. The DNA cassette of claim 4, which has a following nucleotide sequence (SEQ ID NO: 15) :
5 ' -ATGGGCAAACGAGAGCATTGGTCACACGGGTGGTACCCCGGGGGGAAGAGAGAGC ACTGGTCCCACGGGTGGTACCCAGGCGGGAAGAGAGAGCACTGGTCCCACGGGTGGTA CCCAGGCGGGAAGAGAGAGCACTGGTCCCACGGGTGGTACCCAGGCGGGAAGAGACTC GAGAAGCTTTGACAGCTGTCAAAGCTT-3' .
6. The DNA cassette of claim 1, wherein the linker peptide cleavable by a protease has an amino acid link or an amino acid sequence selected from the group consisting of:
(i) lysine and arginine, which are cleavable by trypsin; (ii) asparagine, cleavable by asparaginylendopeptidase;
(iii) arginine, cleavable by arginylendopeptidase; (iv) lysine, cleavable by Achromobacter protease I; (v) glutamine, cleavable by Staphylococcus aureus V8 protease;
(vi) Glu-Asn-Leu-Tyr-Phe-Gln-Gly, cleavable by tTEV protease; and
(vii) Ile-Glu-Gly-Arg, cleavable by factor Xa.
7. The DNA cassette of claim 6, wherein the linker peptide is Gly-Lys-Arg.
8. The DNA cassette of claim 1, wherein the linker peptide cleavable by a chemical agent has an amino acid sequence containing methionine which is cleavable by cyanogen bromide .
9. A process for preparing a DNA cassette which comprises ligating a basic DNA unit having a 5' -cohesive ended form or 3' -cohesive ended form, the basic DNA unit composed of a double stranded DNA region encoding a biologically active peptide and two complementary single stranded DNA regions protruding from 5'- or 3 '-ends thereof encoding a linker peptide cleavable by a protease or a chemical agent.
10. A DNA cassette which comprises two or more tandem repeating units of a nucleotide sequence encoding a biologically active peptide having a C-terminal amino acid residue which is cleavable by a protease or a chemical agent .
11. The DNA cassette of claim 10, wherein the biologically active peptide is comprised of 2 to 200 amino acid" residues .
12. The DNA cassette of claim 10, wherein the C- terminal amino acid residue is selected from the group consisting of:
(i) lysine and arginine, which are cleavable by trypsin; (ii) asparagine, cleavable by asparaginylendopeptidase;
(iii) arginine, cleavable by arginylendopeptidase; (iv) lysine, cleavable by Achromobacter protease I; and (v) glutamine, cleavable by Staphylococcus aureus V8 protease.
13. The DNA cassette of claim 10, wherein the C- terminal amino acid residue is methionine which is cleavable by cyanogen bromide .
14. An expression vector comprising the DNA cassette of any of claims 1 to 8 and 10 to 13.
15. The expression vector of claim 14, which is pRSET- B-cGnRH-II' -4R*.
16. A microorganism transformed with the expression vector of claim 14.
17. The microorganism of claim 16, which is IL. coli transformed with pRSET-B-cGnRH-II ' -4R*.
18. A process for preparing a biologically active peptide or an analog thereof which comprises the steps of: (a) preparing an expression vector comprising a DNA cassette containing two or more tandem repeating units of a nucleotide sequence encoding a biologically active peptide and a linker peptide attached thereto, the linker peptide being cleavable by a protease or a chemical agent; (b) transforming a microorganism with the expression vector; (c) culturing the transformed microorganism to produce a multimeric peptide expressed by the DNA cassette; and (d) recovering and digesting the multimeric peptide with the protease or the chemical agent to obtain the biologically active peptide or an analog thereof carrying one or more amino acid residues originating from the linker peptide.
19. A process for preparing a biologically active peptide which comprises the steps of:
(a) preparing an expression vector comprising a DNA cassette containing two or more tandem repeating units of a nucleotide sequence encoding a biologically active peptide having a C-terminal amino acid residue which is cleavable by a protease or a chemical agent;
(b) transforming a microorganism with the expression vector; (c) culturing the transformed microorganism to produce a multimeric peptide expressed by the DNA cassette; and (d) recovering and digesting the multimeric peptide with the protease or the chemical agent to obtain the biologically active peptide.
PCT/KR1999/000559 1998-09-19 1999-09-17 Dna cassette encoding a multimer of a biologically active peptide and a cleavable linker attached thereto and process for preparing the biologically active peptide WO2000017336A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU57626/99A AU5762699A (en) 1998-09-19 1999-09-17 Dna cassette encoding a multimer of a biologically active peptide and a cleavable linker attached thereto and process for preparing the biologically active peptide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR19980038835 1998-09-19
KR1998/38835 1998-09-19

Publications (1)

Publication Number Publication Date
WO2000017336A1 true WO2000017336A1 (en) 2000-03-30

Family

ID=19551195

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR1999/000559 WO2000017336A1 (en) 1998-09-19 1999-09-17 Dna cassette encoding a multimer of a biologically active peptide and a cleavable linker attached thereto and process for preparing the biologically active peptide

Country Status (2)

Country Link
AU (1) AU5762699A (en)
WO (1) WO2000017336A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004015112A1 (en) * 2002-07-24 2004-02-19 Fresenius Kabi Deutschland Gmbh Dns-constructs for the production of peptides
WO2004106525A1 (en) * 2003-06-03 2004-12-09 Shanghai Centre Of Research & Development Of New Drugs A fusion protein suitable to be expressed high effectively and the production method thereof
AU2013234860B2 (en) * 2012-03-19 2016-01-21 Madeleine Pharmaceuticals Pty Ltd Method of producing a recombinant peptide

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0163406A1 (en) * 1984-05-01 1985-12-04 National Research Council Of Canada Novel polypeptide expression method
DE3102721C2 (en) * 1980-01-30 1988-11-10 G.D. Searle & Co., Skokie, Ill., Us
WO1992015679A1 (en) * 1991-03-01 1992-09-17 Protein Engineering Corporation Improved epitode displaying phage
EP0505846A1 (en) * 1991-03-27 1992-09-30 Sanwa Kagaku Kenkyusho Co., Ltd. Process for converting fused protein into active type human motilin analogues and purifying the analogues
EP0532043A2 (en) * 1991-09-13 1993-03-17 Hitachi, Ltd. Factor Xa linker DNA
EP0622459A1 (en) * 1993-04-26 1994-11-02 Sanwa Kagaku Kenkyusho Co., Ltd. Fused proteins for preparing vasoactive intestinal polypeptide analogs, method of preparing same and recombinant plasmids and transformant microorganisms

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3102721C2 (en) * 1980-01-30 1988-11-10 G.D. Searle & Co., Skokie, Ill., Us
EP0163406A1 (en) * 1984-05-01 1985-12-04 National Research Council Of Canada Novel polypeptide expression method
WO1992015679A1 (en) * 1991-03-01 1992-09-17 Protein Engineering Corporation Improved epitode displaying phage
EP0505846A1 (en) * 1991-03-27 1992-09-30 Sanwa Kagaku Kenkyusho Co., Ltd. Process for converting fused protein into active type human motilin analogues and purifying the analogues
EP0532043A2 (en) * 1991-09-13 1993-03-17 Hitachi, Ltd. Factor Xa linker DNA
EP0622459A1 (en) * 1993-04-26 1994-11-02 Sanwa Kagaku Kenkyusho Co., Ltd. Fused proteins for preparing vasoactive intestinal polypeptide analogs, method of preparing same and recombinant plasmids and transformant microorganisms

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 121, no. 5, 1 August 1994, Columbus, Ohio, US; abstract no. 53271N, KULIOPULOS ET AL.: "Production, Purification and Clearage of Tandem Repeats of Recombinant Peptides" page 430; *
J. AM. CHEM. SOC.,, vol. 116, no. 11, 1994, (ENG), pages 4599 - 4607 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004015112A1 (en) * 2002-07-24 2004-02-19 Fresenius Kabi Deutschland Gmbh Dns-constructs for the production of peptides
WO2004106525A1 (en) * 2003-06-03 2004-12-09 Shanghai Centre Of Research & Development Of New Drugs A fusion protein suitable to be expressed high effectively and the production method thereof
CN1298742C (en) * 2003-06-03 2007-02-07 上海新药研究开发中心 A fusion protein suitable to highly effective expression and production method thereof
US7795384B2 (en) 2003-06-03 2010-09-14 Shanghai Centre Of Research & Development Of New Drugs Fusion protein suitable for high efficiency expression and the production method thereof
AU2013234860B2 (en) * 2012-03-19 2016-01-21 Madeleine Pharmaceuticals Pty Ltd Method of producing a recombinant peptide

Also Published As

Publication number Publication date
AU5762699A (en) 2000-04-10

Similar Documents

Publication Publication Date Title
KR100227167B1 (en) Fusion protein containing n-terminal fragments of human serum albumin
KR860001305B1 (en) Expression linkers
CA1340522C (en) Fusion proteins containing neighbouring histidines for improved purification
EP0230869B1 (en) Construction of an igg binding protein to facilitate downstream processing using protein engineering
EP1114062B1 (en) Modified e.coli enterotoxin ii signal peptide and a microorganism expressing a fusion protein of said peptide and a heterologous protein
US4888286A (en) Production of gene and protein analogs through synthetic gene design using double stranded synthetic oligonucleotides
JP3362050B2 (en) Method for mass production of antimicrobial peptides
EP0205475B2 (en) Recombinant methods for production of serine protease inhibitors and dna sequences useful for same
WO1996023890A1 (en) Secretory signal gene and expression vector having the same
AU757147C (en) Modified human granulocyte-colony stimulating factor and process for producing same
WO1984003519A1 (en) Modified signal peptides
US20160168226A1 (en) Process for production of insulin and insulin analogues
Wingender et al. Expression of human parathyroid hormone in Escherichia coli
JP3319605B2 (en) A method for producing exogenous proteins in Streptomyces
JPH067187A (en) Fusion product of protected peptide and alpha-hanp
EP0220482B1 (en) Novel plasmid and use thereof
WO2000017336A1 (en) Dna cassette encoding a multimer of a biologically active peptide and a cleavable linker attached thereto and process for preparing the biologically active peptide
US20030153049A1 (en) Escherichia coli strain secreting human granulocyte colony stimulating factor (g-csf)
EP0063494A2 (en) Method for producing protein from a microorganism, microorganisms for use in such method and creation thereof, vectors for use in said creation, and protein produced thereby, and transformant culture derived from said microorganisms
US4935351A (en) Process for preparing oligopeptide
Mesyanzhinov et al. A proposed structure of bacteriophage T4 gene product 22—a major prohead scaffolding core protein
US6187589B1 (en) Vectorial cloning system of DNA
KR100379025B1 (en) Dna cassette encoding a multimer of a biologically active peptide and a cleavable linker peptide attached thereto and process for preparing the biologically active peptide
Lee et al. A novel technique for the effective production of short peptide analogs from concatameric short peptide multimers
EP0267795A2 (en) Murine-interleukin-2 muteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase